BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33660007)

  • 21. Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
    Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Schlick K; Huemer F; Deutsch A; Neumeister P; Greil R; Pichler M; Egle A
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1501-8. PubMed ID: 26656519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers.
    Liu Y; Sheng L; Hua H; Zhou J; Zhao Y; Wang B
    Technol Cancer Res Treat; 2023; 22():15330338231180785. PubMed ID: 37551117
    [No Abstract]   [Full Text] [Related]  

  • 24. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
    Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
    Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Berry B; Chhanabhai M; Fitzgerald C; Gill K; Hoskins P; Klasa R; Savage KJ; Shenkier T; Sutherland J; Gascoyne RD; Connors JM
    Blood; 2007 Mar; 109(5):1857-61. PubMed ID: 17105812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
    Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
    Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
    Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
    J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of the enhanced International Prognostic Index (NCCN-IPI) for cases with diffuse large B-cell lymphoma].
    Yamada A; Tamura H; Asayama T; Moriya K; Okuyama N; Kondo-Onodera A; Hamada Y; Ishibashi M; Yokose N; Tanosaki S; Inokuchi K
    Rinsho Ketsueki; 2015 Jul; 56(7):915-8. PubMed ID: 26256931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.
    Tchernonog E; Faurie P; Coppo P; Monjanel H; Bonnet A; Algarte Génin M; Mercier M; Dupuis J; Bijou F; Herbaux C; Delmer A; Fabiani B; Besson C; Le Gouill S; Gyan E; Laurent C; Ghesquieres H; Cartron G
    Ann Oncol; 2017 Apr; 28(4):843-848. PubMed ID: 28031174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
    Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
    Lu CS; Chen JH; Huang TC; Wu YY; Chang PY; Dai MS; Chen YC; Ho CL
    Leuk Lymphoma; 2015 Jul; 56(7):2047-55. PubMed ID: 25382616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
    Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
    Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmablastic lymphoma of the gastrointestinal tract: A rare entity with a dismal prognosis.
    Komaranchath AS; Haleshappa RA; Kuntegowdenahalli LC; Kumar RV; Dasappa L; Babu G
    Indian J Cancer; 2016; 53(4):529-533. PubMed ID: 28485344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.